NCT03573401: Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). |
|
|
| Active, not recruiting | 3 | 186 | US | Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), ALA-PDT, Ameluz®-PDT, Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient) | Biofrontera Bioscience GmbH | Superficial Basal Cell Carcinoma | 03/24 | 02/29 | | |
NCT03887377: The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation |
|
|
| Enrolling by invitation | 2/3 | 22 | US | Botulinum Toxins, Dysport, BTXa, abobotulinumtoxinA, Normal saline, Placebo | Henry Ford Health System, Galderma R&D | Scar, Hypertrophic Scar, Mammary Disorder | 12/24 | 12/24 | | |
